Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Oxford Biodynamics PLC currently has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 4 distinct examiners, which suggests a variety of perspectives within the examination process. The portfolio spans 3 distinct art units, indicating that the company's biotechnology research touches upon multiple specialized administrative divisions at the patent office.
CASH, KAILEY ELIZABETH is the busiest examiner for the company, currently managing 1 pending office action. Because the active matters are spread across different individuals, no single examiner holds a majority of the workload. This distribution across 3 distinct art units means the prosecution strategy must account for varying examiner behaviors and art unit norms. The current active pipeline for the company's pharmaceutical and biotech interests involves multiple points of contact within the patent office. Practitioners should prepare for varied feedback across the 4 pending office actions to ensure consistent claim scope.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (25%) |
| §101 + other | 2 (50%) |
| §112 only | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CASH, KAILEY ELIZABETH | 1 | 28.6% | +64.3% |
| MYERS, CARLA J | 1 | 49.3% | +46.1% |
| SITTON, JEHANNE SOUAYA | 1 | 53.2% | +48.0% |
| LEITH, NANCY J | 1 | 74.7% | +44.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260306 | ANALYSIS METHOD | CASH, KAILEY ELIZABETH | — |
| 18000243 | DETECTING A CHROMOSOME CONFIRMATION AS MARKER FOR FIBROSIS, E.G. SLERODERMA | SITTON, JEHANNE SOUAYA | — |
| 16949333 | METHODS OF DETECTING LONG RANGE CHROMOSOMAL INTERACTIONS | LEITH, NANCY J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260306 | ANALYSIS METHOD | CASH, KAILEY ELIZABETH | — |
| 18247133 | DISEASE MARKER | MYERS, CARLA J | — |
| 18000243 | DETECTING A CHROMOSOME CONFIRMATION AS MARKER FOR FIBROSIS, E.G. SLERODERMA | SITTON, JEHANNE SOUAYA | — |
| 16949333 | METHODS OF DETECTING LONG RANGE CHROMOSOMAL INTERACTIONS | LEITH, NANCY J | — |
| Art Unit | Apps |
|---|---|
| 1682 | 2 |
| 1683 | 1 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18260306 | ANALYSIS METHOD | CASH, KAILEY ELIZABETH | 1683 | §101§112DP | Non-Final OA | — | Pending | Jul 03, 2023 |
| 18247133 | DISEASE MARKER | MYERS, CARLA J | 1682 | §112Other | Final Rejection | — | Pending | Mar 29, 2023 |
| 18000243 | DETECTING A CHROMOSOME CONFIRMATION AS MARKER FOR FIBROSIS, E.G. SLERODERMA | SITTON, JEHANNE SOUAYA | 1682 | §101§112 | Non-Final OA | — | Pending | Nov 29, 2022 |
| 16949333 | METHODS OF DETECTING LONG RANGE CHROMOSOMAL INTERACTIONS | LEITH, NANCY J | 1636 | §101Other | Non-Final OA | — | Pending | Oct 26, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial